Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy

May 15, 2025 10:58 AM ETCellectis S.A. (CLLS) StockCLLS
Galzus Research
2.17K Followers
(7min)

Summary

  • Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies.
  • The financial picture remains strong, bolstered further by a partnership with AstraZeneca.
  • Promised data readouts in late 2025 represent important potential catalysts.
  • I remain tentatively optimistic about CLLS despite the decline in market value.

Profile side view closeup of woman hand showing like or thumbs up, approved, positive feedback.

Khosrork/iStock via Getty Images

Topline Summary and Update

Cellectis S.A. (NASDAQ:CLLS) is a company I've expressed tentative optimism regarding their upcoming data updates in 2025. In particular, the company is positioning itself to truly begin answering questions about their pipeline. Today, I want

This article was written by

2.17K Followers
I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About CLLS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CLLS

Related Stocks

SymbolLast Price% Chg
CLLS
--